Carregant...

The Risks of miRNA Therapeutics: In a Drug Target Perspective

RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs, were approved by the Food and Drug Administration in 2018 and 2019, respectively. However, there is rare news on the advance of miRNA drugs (another therapeutic similar to siRNA drug). Here we report the existing ob...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Des Devel Ther
Autors principals: Zhang, Song, Cheng, Zhujun, Wang, Yanan, Han, Tianyu
Format: Artigo
Idioma:Inglês
Publicat: Dove 2021
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7910153/
https://ncbi.nlm.nih.gov/pubmed/33654378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S288859
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!